Daxor Reveals New Insights in Heart Failure Treatment

Partner News | Published: Monday, October 24, 2022

Daxor Corporation, the global leader in blood volume measurement technology, recently presented new research at the Heart Failure Society of America (HFSA) Annual Scientific Meeting.

Blood volume analysis (BVA) is an innovative diagnostic test that provides key data on congestion management and anemia in a single test. This allows care teams to understand with precision, the intravascular volume status of heart failure (HF) patients and solve the significant challenge of accurately managing fluid levels and red cell derangements. Best practices for implementation of BVA enable the care team to incorporate testing into both the inpatient and outpatient HF care settings, providing the guidance needed by clinicians to drive improvement in key patient outcomes. 

Daxor presented three studies at HFS:

Length of Stay After Blood Volume Analysis in Hospitalized Heart Failure

Showed those who received BVA-guided treatment on the day of admission to the hospital had a significant (p <0.001) lower total LOS than controls (2.04 vs. 4.56 days) and significantly improved outcomes (lower 30-day readmissions and 365-day mortality). 

Heart Failure Outcomes with Volume-guided Management in An Over-65 Population

Showed a cohort of patients experienced markedly better outcomes vs. controls for 30-day readmissions (12.0% vs. 27.0%, p <.001), 30-day mortality (2.3% vs. 11.8%, p <.001), and 365-day mortality (5.6% vs. 36.8%, p <.001) rates.  

Correlation Between Pressure and Volume in Ambulatory Heart Failure: Sex-Specific Analysis

Showed there was a discordance between pressure and volume measures in both men and women suggesting preferential response to diuretics to improve congestion in men.

Upcoming Webinar

Join MedAxiom and Daxor on Nov. 17 from 1-2 p.m. ET for a webinar on Best Practices for Using Blood Volume Analysis (BVA) to Reduce Heart Failure LOS, Readmissions, Mortality and Costs. This webinar takes a deep dive into the best practices for implementing the innovative diagnostic BVA which has been shown to improve outcomes and reduce the total cost of care in both the inpatient and outpatient settings.


About MedAxiom

MedAxiom is transforming cardiovascular care by combining the knowledge and power of 450+ cardiovascular organization members, thousands of administrators, clinicians and coders and 40+ industry partners. Through the delivery of proprietary tools, smart data and proven strategies, MedAxiom helps cardiovascular organizations achieve the Quadruple Aim of better outcomes, lower costs, improved patient experience and improved clinician experience.

For additional information, visit MedAxiom.com.

About Daxor Corporation

Daxor Corporation (Nasdaq: DXR), is the global leader in blood volume measurement technology focused on blood volume testing innovation. We developed and market the BVA-100® (Blood Volume Analyzer), the only diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms. Over 60,000+ tests have been performed at leading hospital centers across the U.S., enhancing hospital performance metrics in a broad range of surgical and medical conditions, including significantly reducing mortality and readmissions in heart failure and critical care. Daxor has several ongoing multicenter trials in the areas of COVID-19 and heart failure treatment with support from the NIH and is under contract developing analyzers to improve combat casualty care with the U.S. Department of Defense. Daxor’s mission is to advance healthcare by enabling optimal fluid management with blood volume analysis. Daxor’s vision is optimal blood volume for all. For more information, please visit our website at Daxor.com.


This site uses cookies to improve your experience.

By continuing to use our site, you agree to our Cookie Policy, Privacy Policy and Terms of Use.